by Portfolio Grader | October 26, 2012 8:03 am
This week, five Pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Johnson & Johnson (NYSE:JNJ) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. In Portfolio Grader’s specific subcategory of Equity, JNJ also gets an A. The current dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of JNJ stock.
Novartis (NYSE:NVS) is seeing ratings go up from a C last week to a B this week. Novartis manufactures pharmaceutical and consumer healthcare products. At present, the stock has a dividend yield of 2.5%. For more information, get Portfolio Grader’s complete analysis of NVS stock.
Acura Pharmaceuticals (NASDAQ:ACUR) earns a B this week, jumping up from last week’s grade of C. Acura Pharmaceuticals engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. For more information, get Portfolio Grader’s complete analysis of ACUR stock.
This week, Pfizer (NYSE:PFE) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Pfizer is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. For more information, get Portfolio Grader’s complete analysis of PFE stock.
This week, SciClone Pharmaceuticals (NASDAQ:SCLN) pushes up from a B to a A rating. SciClone Pharmaceuticals is a global biopharmaceutical company that acquires, develops, and commercializes specialist-oriented drugs. The stock has a trailing PE Ratio of 7.80. For more information, get Portfolio Grader’s complete analysis of SCLN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2012/10/5-pharmaceutical-stocks-to-buy-now-jnj-nvs-acur/
Short URL: http://investorplace.com/?p=249982
Copyright ©2013 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.